Literature DB >> 1859487

Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study.

M Petri1, M Genovese, E Engle, M Hochberg.   

Abstract

The course of systemic lupus erythematosus (SLE) is characterized by exacerbations (or flares) and remissions of disease activity. As part of an ongoing prospective cohort study, 3 disease activity indices, the physician's global assessment, the Lupus Activity Index, and the University of Toronto SLE Disease Activity Index, have been recorded, at least quarterly since 1987, on 185 SLE patients. We developed a definition of SLE flare and a description of its clinical epidemiology. Disease flare was defined as a change of greater than or equal to 1.0 in the physician's global assessment of disease activity (measured on a 0-3 scale) from the previous visit or from a visit within the last 93 days. Of the 185 patients, 98 (53%) had greater than or equal to 1 flare; the total number of flares was 146. The incidence of flare was 0.65 per patient-year of followup. The median time from the first study visit to a flare was 12 months. Flares were frequently characterized by constitutional symptoms, musculoskeletal involvement, cutaneous involvement, and decreasing levels of C3 and C4. At the time of flare, the mean University of Toronto SLE Disease Activity Index score increased by 3.0 and the mean Lupus Activity Index score (modified to omit the physician's global assessment) increased by 0.26. Overall, 44.8% of the flares prompted a change in treatment. Patients who experienced flares fulfilled more of the SLE criteria at entry and had been followed up for a longer duration after entry into the study, compared with those who did not have flares.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1859487     DOI: 10.1002/art.1780340802

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  59 in total

1.  Fine specificity of autoantibodies to calreticulin: epitope mapping and characterization.

Authors:  P Eggleton; F J Ward; S Johnson; M A Khamashta; G R Hughes; V A Hajela; M Michalak; E F Corbett; N A Staines; K B Reid
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

Review 2.  The use of laboratory tests in the diagnosis of SLE.

Authors:  W Egner
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

3.  An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity.

Authors:  Emily C Baechler; Jason W Bauer; Catherine A Slattery; Ward A Ortmann; Karl J Espe; Jill Novitzke; Steven R Ytterberg; Peter K Gregersen; Timothy W Behrens; Ann M Reed
Journal:  Mol Med       Date:  2007 Jan-Feb       Impact factor: 6.354

4.  The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation.

Authors:  H Bootsma; P E Spronk; E J Ter Borg; E J Hummel; G de Boer; P C Limburg; C G Kallenberg
Journal:  Ann Rheum Dis       Date:  1997-11       Impact factor: 19.103

5.  A copula model for marked point processes.

Authors:  Liqun Diao; Richard J Cook; Ker-Ai Lee
Journal:  Lifetime Data Anal       Date:  2013-05-10       Impact factor: 1.588

6.  Anti-C1q autoantibodies as markers of renal involvement in childhood-onset systemic lupus erythematosus.

Authors:  Cécile Picard; Jean-Christophe Lega; Bruno Ranchin; Pierre Cochat; Natalia Cabrera; Nicole Fabien; Alexandre Belot
Journal:  Pediatr Nephrol       Date:  2017-03-25       Impact factor: 3.714

7.  Adrenal gland abnormalities detected by magnetic resonance imaging in patients with antiphospholipid syndrome.

Authors:  A A Shahin; S M El Desouky; M Y Awadallah; D E Megahed
Journal:  Z Rheumatol       Date:  2017-03       Impact factor: 1.372

8.  Assessment of lupus: where are we now?

Authors:  E Hay; C Gordon; P Emery
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

9.  Major flares in women with SLE on combined oral contraception.

Authors:  D A Whitelaw; S J Jessop
Journal:  Clin Rheumatol       Date:  2007-05-09       Impact factor: 2.980

10.  Circulating intercellular adhesion molecule 1 as a new activity marker in patients with systemic lupus erythematosus.

Authors:  E Kling; S Bieg; M Boehme; W A Scherbaum
Journal:  Clin Investig       Date:  1993-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.